Long-term safety and efficacy of armodafinil in bipolar depression: A 6-month open-label extension study

Terence A. Ketter, Jess Amchin, Mark A Frye, Nicholas Gross

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background Safe/well-tolerated treatments for bipolar I depression remain limited. We assessed safety/tolerability of adjunctive open-label armodafinil, a wakefulness-promoting agent evaluated in 3 acute, controlled efficacy studies with variable efficacy results. Methods Completers of three 8-week, double-blind, placebo-controlled adjunctive armodafinil studies (150-200 mg/day added to ongoing stable maintenance doses of 1 or 2 protocol-defined mood stabilizers) in bipolar I depression could enter this 6-month, open-label extension study. Objectives included evaluation of safety/tolerability (primary) and efficacy (secondary). Results 867 patients enrolled; 863 received ≥1 dose of armodafinil and 506 (58%) completed the 6-month study. Headache, insomnia, and anxiety were the most common adverse events (AEs) reported, whereas akathisia, nausea, sedation/somnolence, and weight increase were uncommon. Mean measures assessing emergence of mania, anxiety, insomnia, or suicidality showed no worsening. Discontinuations due to AEs occurred in 57 (7%) patients. Serious AEs occurred in 27 (3%) patients and were considered treatment-related in 8 (1%) patients. Depressive symptoms improved over the 6 months, as did patient functioning. Limitations Lack of placebo control. Conclusions Adjunctive armodafinil was generally safe and well tolerated over 6 months of open-label treatment at 150-200 mg/day when taken with protocol-defined mood stabilizers for bipolar I depression. This 6-month open-label study suggested that armodafinil augmentation of bipolar maintenance therapies may have a favorable risk profile and may improve depressive symptoms in some patients with bipolar I depression.

Original languageEnglish (US)
Pages (from-to)51-57
Number of pages7
JournalJournal of Affective Disorders
Volume197
DOIs
StatePublished - Jun 1 2016

Fingerprint

Bipolar Disorder
Safety
Sleep Initiation and Maintenance Disorders
Wakefulness-Promoting Agents
Anxiety
Placebos
Depression
Psychomotor Agitation
Therapeutics
Nausea
Headache
armodafinil
Weights and Measures

Keywords

  • Armodafinil
  • Bipolar depression
  • Bipolar I disorder
  • Long-term safety
  • Wakefulness

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Long-term safety and efficacy of armodafinil in bipolar depression : A 6-month open-label extension study. / Ketter, Terence A.; Amchin, Jess; Frye, Mark A; Gross, Nicholas.

In: Journal of Affective Disorders, Vol. 197, 01.06.2016, p. 51-57.

Research output: Contribution to journalArticle

@article{ef4c9dacd16943009f3a302aab9b80d5,
title = "Long-term safety and efficacy of armodafinil in bipolar depression: A 6-month open-label extension study",
abstract = "Background Safe/well-tolerated treatments for bipolar I depression remain limited. We assessed safety/tolerability of adjunctive open-label armodafinil, a wakefulness-promoting agent evaluated in 3 acute, controlled efficacy studies with variable efficacy results. Methods Completers of three 8-week, double-blind, placebo-controlled adjunctive armodafinil studies (150-200 mg/day added to ongoing stable maintenance doses of 1 or 2 protocol-defined mood stabilizers) in bipolar I depression could enter this 6-month, open-label extension study. Objectives included evaluation of safety/tolerability (primary) and efficacy (secondary). Results 867 patients enrolled; 863 received ≥1 dose of armodafinil and 506 (58{\%}) completed the 6-month study. Headache, insomnia, and anxiety were the most common adverse events (AEs) reported, whereas akathisia, nausea, sedation/somnolence, and weight increase were uncommon. Mean measures assessing emergence of mania, anxiety, insomnia, or suicidality showed no worsening. Discontinuations due to AEs occurred in 57 (7{\%}) patients. Serious AEs occurred in 27 (3{\%}) patients and were considered treatment-related in 8 (1{\%}) patients. Depressive symptoms improved over the 6 months, as did patient functioning. Limitations Lack of placebo control. Conclusions Adjunctive armodafinil was generally safe and well tolerated over 6 months of open-label treatment at 150-200 mg/day when taken with protocol-defined mood stabilizers for bipolar I depression. This 6-month open-label study suggested that armodafinil augmentation of bipolar maintenance therapies may have a favorable risk profile and may improve depressive symptoms in some patients with bipolar I depression.",
keywords = "Armodafinil, Bipolar depression, Bipolar I disorder, Long-term safety, Wakefulness",
author = "Ketter, {Terence A.} and Jess Amchin and Frye, {Mark A} and Nicholas Gross",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.jad.2016.02.050",
language = "English (US)",
volume = "197",
pages = "51--57",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",

}

TY - JOUR

T1 - Long-term safety and efficacy of armodafinil in bipolar depression

T2 - A 6-month open-label extension study

AU - Ketter, Terence A.

AU - Amchin, Jess

AU - Frye, Mark A

AU - Gross, Nicholas

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Background Safe/well-tolerated treatments for bipolar I depression remain limited. We assessed safety/tolerability of adjunctive open-label armodafinil, a wakefulness-promoting agent evaluated in 3 acute, controlled efficacy studies with variable efficacy results. Methods Completers of three 8-week, double-blind, placebo-controlled adjunctive armodafinil studies (150-200 mg/day added to ongoing stable maintenance doses of 1 or 2 protocol-defined mood stabilizers) in bipolar I depression could enter this 6-month, open-label extension study. Objectives included evaluation of safety/tolerability (primary) and efficacy (secondary). Results 867 patients enrolled; 863 received ≥1 dose of armodafinil and 506 (58%) completed the 6-month study. Headache, insomnia, and anxiety were the most common adverse events (AEs) reported, whereas akathisia, nausea, sedation/somnolence, and weight increase were uncommon. Mean measures assessing emergence of mania, anxiety, insomnia, or suicidality showed no worsening. Discontinuations due to AEs occurred in 57 (7%) patients. Serious AEs occurred in 27 (3%) patients and were considered treatment-related in 8 (1%) patients. Depressive symptoms improved over the 6 months, as did patient functioning. Limitations Lack of placebo control. Conclusions Adjunctive armodafinil was generally safe and well tolerated over 6 months of open-label treatment at 150-200 mg/day when taken with protocol-defined mood stabilizers for bipolar I depression. This 6-month open-label study suggested that armodafinil augmentation of bipolar maintenance therapies may have a favorable risk profile and may improve depressive symptoms in some patients with bipolar I depression.

AB - Background Safe/well-tolerated treatments for bipolar I depression remain limited. We assessed safety/tolerability of adjunctive open-label armodafinil, a wakefulness-promoting agent evaluated in 3 acute, controlled efficacy studies with variable efficacy results. Methods Completers of three 8-week, double-blind, placebo-controlled adjunctive armodafinil studies (150-200 mg/day added to ongoing stable maintenance doses of 1 or 2 protocol-defined mood stabilizers) in bipolar I depression could enter this 6-month, open-label extension study. Objectives included evaluation of safety/tolerability (primary) and efficacy (secondary). Results 867 patients enrolled; 863 received ≥1 dose of armodafinil and 506 (58%) completed the 6-month study. Headache, insomnia, and anxiety were the most common adverse events (AEs) reported, whereas akathisia, nausea, sedation/somnolence, and weight increase were uncommon. Mean measures assessing emergence of mania, anxiety, insomnia, or suicidality showed no worsening. Discontinuations due to AEs occurred in 57 (7%) patients. Serious AEs occurred in 27 (3%) patients and were considered treatment-related in 8 (1%) patients. Depressive symptoms improved over the 6 months, as did patient functioning. Limitations Lack of placebo control. Conclusions Adjunctive armodafinil was generally safe and well tolerated over 6 months of open-label treatment at 150-200 mg/day when taken with protocol-defined mood stabilizers for bipolar I depression. This 6-month open-label study suggested that armodafinil augmentation of bipolar maintenance therapies may have a favorable risk profile and may improve depressive symptoms in some patients with bipolar I depression.

KW - Armodafinil

KW - Bipolar depression

KW - Bipolar I disorder

KW - Long-term safety

KW - Wakefulness

UR - http://www.scopus.com/inward/record.url?scp=84960102820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960102820&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2016.02.050

DO - 10.1016/j.jad.2016.02.050

M3 - Article

C2 - 26970266

AN - SCOPUS:84960102820

VL - 197

SP - 51

EP - 57

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

ER -